An Open-Label, Multicenter, Phase 1/2 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-tumor Activity of Systemic ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malignant Melanoma (Adherex Protocol Number AHX-01-007).

Inclusion Criteria:

- Signed written informed consent

- Male and female patients > or = 18 years of age with diagnosis of melanoma for which
treatment with Normothermic Isolated Limb Infusion (ILI) of melphalan would be
appropriate

- Measurable disease

- Disease site(s) must be distal to the planned site of tourniquet placement

- Available for immunohistochemical testing of N-cadherin expression tumor tissue

- Adequate performance status and organ function, as evidenced by hematological and
biochemical blood testing and ECG

Exclusion Criteria:

- Receipt of ADH-1 prior to this clinical study (prior melphalan via ILI, is okay)

- Stage IV melanoma

- Chemotherapy, radiotherapy, or any other investigational drug within 4 weeks before
study entry

- History of tumors that have shown clinically significant evidence of active bleeding
within 12 weeks before study entry

- Stroke, major surgery, or other major tissue injury within 4 weeks before study entry

- Uncontrolled congestive heart failure, coronary artery disease, or life threatening
arrhythmias; myocardial infarction within 12 months; significant electrocardiogram
(ECG) abnormalities

- Allergic reaction to any therapeutic peptide or to melphalan